Understanding the Role of AGEs and sRAGE in Diabetes: Insights from Recent Research

Originally published online at https://arbonahealthhub.com/2024/12/06/understanding-the-role-of-ages-and-srage-in-diabetes-insights-from-recent-research/ This article examines how advanced glycation end products (AGEs) and their interaction with the receptor for AGEs (RAGE) contribute to the complications of type 1 and type 2 diabetes by triggering inflammation and oxidative stress. It explains that AGEs accumulate in hyperglycemia and bind full-length RAGE (fl-RAGE) on cell surfaces, activating harmful signaling pathways, whereas soluble RAGE forms (sRAGE, including esRAGE and cRAGE) act as “decoy” receptors to neutralize AGEs and mitigate damage. A systematic review by Chen et al. (2024) clarified that sRAGE levels rise in long-standing type 1 diabetes and in type 2 diabetes with complications, likely as a compensatory response to chronic metabolic stress, but are lower in newly diagnosed type 2 cases. The article highlights that diabetes medications such as insulin and oral hypoglycemics can further increase sRAGE, suggesting a protective mechanism, and underscores the need for tailored treatment strategies and more research into the genetic and molecular factors that regulate sRAGE in diabetes management.